Diagnosis and treatment of CD20 negative B cell lymphomas

被引：25
|
作者：
Katchi, Tasleem
Liu, Delong [1 ]
机构：
[1] New York Med Coll, Div Hematol & Oncol, Valhalla, NY 10595 USA
来源：
BIOMARKER RESEARCH | 2017年 / 5卷
关键词：
DOSE-ADJUSTED EPOCH; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BRUTON TYROSINE KINASE; CODOX-M/IVAC; BURKITT-LYMPHOMA; PHASE-II; HODGKINS-LYMPHOMA; POOR-PROGNOSIS; FOLLOW-UP;
D O I：
10.1186/s40364-017-0088-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20-negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman's disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Conventional and pretargeted radioimmunotherapy of B cell lymphomas using CD20, CD22, and HLA DR as target antigens
    Press, O.
    Wilbur, S.
    Lin, Y.
    Hamlin, D.
    Gopal, A.
    Pagel, J.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 522 - 522
  • [22] Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas
    Perez-Callejo, D.
    Gonzalez-Rincon, J.
    Sanchez, A.
    Provencio, M.
    Sanchez-Beato, M.
    CANCER TREATMENT REVIEWS, 2015, 41 (08) : 680 - 689
  • [23] The Impact of Pre-biopsy Corticosteroids Use on CD20 Staining Pattern in B-cell Lymphomas
    Li, X.
    Krishnamurthy, K.
    Choudhuri, J.
    Wang, Y.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162
  • [24] Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab
    Takashi Sonoki
    Yaqiong Li
    Setsuko Miyanishi
    Hirokazu Nakamine
    Nobuyoshi Hanaoka
    Hiroshi Matsuoka
    Ichiro Mori
    Hideki Nakakuma
    International Journal of Hematology, 2009, 89 : 400 - 402
  • [25] Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab
    Sonoki, Takashi
    Li, Yaqiong
    Miyanishi, Setsuko
    Nakamine, Hirokazu
    Hanaoka, Nobuyoshi
    Matsuoka, Hiroshi
    Mori, Ichiro
    Nakakuma, Hideki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (03) : 400 - 402
  • [26] NKI-B20 (CD20)
    Hekman, A
    HYBRIDOMA, 1996, 15 (02): : 165 - 165
  • [27] Antibody against CD20 in patients with B cell malignancy
    Adamson, PJ
    Zola, H
    Nicholson, IC
    Pilkington, G
    Hohmann, A
    LEUKEMIA RESEARCH, 2001, 25 (12) : 1047 - 1050
  • [28] Isolation and characterization of the B-cell marker CD20
    Ernst, JA
    Li, H
    Kim, HS
    Nakamura, GR
    Yansura, DG
    Vandlen, RL
    BIOCHEMISTRY, 2005, 44 (46) : 15150 - 15158
  • [29] Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas
    Pantelias, Anastasia
    Pagel, John M.
    Hedin, Nathan
    Saganic, Laura
    Wilbur, Shani
    Hamlin, Donald K.
    Wilbur, D. Scott
    Lin, Yukang
    Stone, Diane
    Axworthy, Don
    Gopal, Ajay K.
    Press, Oliver W.
    BLOOD, 2007, 109 (11) : 4980 - 4987
  • [30] Lw-213 Synergizes with Rituximab to Inhibit Diffuse Large B-Cell Lymphomas By Upregulating CD20
    Li, Yuchen
    Li, Hui
    Hui, Hui
    Xu, Jingyan
    BLOOD, 2021, 138
12345